Celldex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.

About CLDX

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. 

CEO
Anthony S. Marucci
CEOAnthony S. Marucci
Employees
186
Employees186
Headquarters
Hampton, New Jersey
HeadquartersHampton, New Jersey
Founded
1983
Founded1983
Employees
186
Employees186

CLDX Key Statistics

Market cap
1.78B
Market cap1.78B
Price-Earnings ratio
-7.93
Price-Earnings ratio-7.93
Dividend yield
Dividend yield
Average volume
692.96K
Average volume692.96K
High today
$26.95
High today$26.95
Low today
$26.39
Low today$26.39
Open price
$26.58
Open price$26.58
Volume
212.08K
Volume212.08K
52 Week high
$30.50
52 Week high$30.50
52 Week low
$14.40
52 Week low$14.40

Stock Snapshot

As of today, Celldex(CLDX) shares are valued at $26.83. The company's market cap stands at 1.78B, with a P/E ratio of -7.93.

During the trading session on 2025-12-25, Celldex(CLDX) shares reached a daily high of $26.95 and a low of $26.39. At a current price of $26.83, the stock is +1.7% higher than the low and still -0.4% under the high.

Trading activity shows a volume of 212.08K, compared to an average daily volume of 692.96K.

Over the past 52 weeks, Celldex(CLDX) stock has traded between a high of $30.50 and a low of $14.40.

Over the past 52 weeks, Celldex(CLDX) stock has traded between a high of $30.50 and a low of $14.40.

CLDX News

Nasdaq 3d
First Week of CLDX August 2026 Options Trading

Investors in Celldex Therapeutics, Inc. (Symbol: CLDX) saw new options become available this week, for the August 2026 expiration. One of the key data points th...

First Week of CLDX August 2026 Options Trading
Simply Wall St 4d
Is Celldex Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?

In December 2025, Celldex Therapeutics began a global Phase 3 EMBARQ-ColdU and SD trial of barzolvolimab in adults with cold urticaria and symptomatic dermograp...

Is Celldex Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?
Simply Wall St 6d
Celldex Therapeutics: Assessing Valuation After a Recent Share Price Uptick

Celldex Therapeutics (CLDX) has been back on traders radar after a recent bump in the share price, leaving many investors wondering whether this clinical stage...

Celldex Therapeutics: Assessing Valuation After a Recent Share Price Uptick

Analyst ratings

81%

of 16 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

People also own

Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.